Mehrdad Mobasher

4.1k total citations · 1 hit paper
39 papers, 1.4k citations indexed

About

Mehrdad Mobasher is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Mehrdad Mobasher has authored 39 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Genetics, 20 papers in Pathology and Forensic Medicine and 15 papers in Oncology. Recurrent topics in Mehrdad Mobasher's work include Chronic Lymphocytic Leukemia Research (25 papers), Lymphoma Diagnosis and Treatment (19 papers) and Acute Lymphoblastic Leukemia research (8 papers). Mehrdad Mobasher is often cited by papers focused on Chronic Lymphocytic Leukemia Research (25 papers), Lymphoma Diagnosis and Treatment (19 papers) and Acute Lymphoblastic Leukemia research (8 papers). Mehrdad Mobasher collaborates with scholars based in United States, Australia and Germany. Mehrdad Mobasher's co-authors include Arnon P. Kater, Peter Hillmen, Thomas J. Kipps, Elizabeth A. Punnoose, Barbara Eichhorst, Kathryn Humphrey, John F. Seymour, Carolyn Owen, Michelle Boyer and Guillaume Cartron and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Mehrdad Mobasher

37 papers receiving 1.4k citations

Hit Papers

Venetoclax–Rituximab in Relapsed or Refractory Chronic Ly... 2018 2026 2020 2023 2018 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    2018 595 citations John F. Seymour, Thomas J. Kipps et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mehrdad Mobasher United States 16 903 672 433 386 345 39 1.4k
Celeste Bello United States 13 640 0.7× 808 1.2× 544 1.3× 247 0.6× 250 0.7× 63 1.3k
Deborah M. Stephens United States 22 1.0k 1.2× 1.1k 1.6× 630 1.5× 342 0.9× 354 1.0× 142 1.7k
Bret Wacker United States 8 744 0.8× 640 1.0× 580 1.3× 435 1.1× 193 0.6× 10 1.4k
Virginia Kelly United States 16 624 0.7× 316 0.5× 394 0.9× 232 0.6× 453 1.3× 34 1.2k
Monali Desai United States 7 950 1.1× 617 0.9× 402 0.9× 362 0.9× 446 1.3× 20 1.6k
Monica Else United Kingdom 22 1.6k 1.7× 1.2k 1.8× 403 0.9× 712 1.8× 320 0.9× 42 2.0k
Timothy J. Murphy United States 9 778 0.9× 799 1.2× 310 0.7× 399 1.0× 158 0.5× 19 1.2k
Kathryn Humphrey United Kingdom 16 1.0k 1.1× 920 1.4× 433 1.0× 369 1.0× 320 0.9× 52 1.4k
Nicole Lamanna United States 21 1.4k 1.5× 1.1k 1.7× 343 0.8× 536 1.4× 428 1.2× 113 1.8k
Ilaria Del Giudice Italy 24 1.5k 1.7× 1.3k 1.9× 408 0.9× 764 2.0× 305 0.9× 82 1.9k

Countries citing papers authored by Mehrdad Mobasher

Since Specialization
Citations

This map shows the geographic impact of Mehrdad Mobasher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mehrdad Mobasher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mehrdad Mobasher more than expected).

Fields of papers citing papers by Mehrdad Mobasher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mehrdad Mobasher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mehrdad Mobasher. The network helps show where Mehrdad Mobasher may publish in the future.

Co-authorship network of co-authors of Mehrdad Mobasher

This figure shows the co-authorship network connecting the top 25 collaborators of Mehrdad Mobasher. A scholar is included among the top collaborators of Mehrdad Mobasher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mehrdad Mobasher. Mehrdad Mobasher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Voss, Martin H., Andrew Hotson, Stephen B. Willingham, et al.. (2020). CD68+ tumor-associated myeloid cells as the target of adenosine-induced gene products and predictor of response to adenosine blockade with ciforadenant (cifo) in renal cell cancer (RCC).. Journal of Clinical Oncology. 38(15_suppl). 5025–5025. 1 indexed citations
3.
Stilgenbauer, Stephan, Franck Morschhauser, Clemens‐Martin Wendtner, et al.. (2020). Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440). Haematologica. 106(11). 2834–2844. 3 indexed citations
4.
Weerdt, Iris de, Tom Hofland, Renate de Boer, et al.. (2019). Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. Blood Advances. 3(17). 2642–2652. 79 indexed citations
5.
Lindeman, Geoffrey J., Aditya Bardia, Rebecca Bowen, et al.. (2019). Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA.. Journal of Clinical Oncology. 37(15_suppl). TPS1108–TPS1108. 2 indexed citations
6.
Luke, Jason J., John D. Powderly, Jaime R. Merchan, et al.. (2019). Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers.. Journal of Clinical Oncology. 37(15_suppl). 2505–2505. 36 indexed citations
7.
8.
Klepin, Heidi D., Avrita Campinha‐Bacote, Wan‐Jen Hong, et al.. (2018). Geriatric Assessment (GA) Measures and Patient-Reported Outcomes (PROs) Among Older Adults Treated in a Phase 1b Study for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). Blood. 132(Supplement 1). 4076–4076. 1 indexed citations
9.
Hillmen, Peter, Arnon P. Kater, John F. Seymour, et al.. (2018). High, durable minimal residual disease negativity (MRD–) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.. Journal of Clinical Oncology. 36(15_suppl). 7508–7508. 3 indexed citations
10.
Costa, Luciano J., Edward A. Stadtmauer, Gareth J. Morgan, et al.. (2018). Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 132(Supplement 1). 303–303. 16 indexed citations
11.
Kater, Arnon P., John F. Seymour, Peter Hillmen, et al.. (2018). Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. Journal of Clinical Oncology. 37(4). 269–277. 198 indexed citations
12.
Davids, Matthew S., John F. Seymour, Andrew W. Roberts, et al.. (2018). Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL.. Journal of Clinical Oncology. 36(15_suppl). 7526–7526. 1 indexed citations
13.
Kater, Arnon P., Peter Hillmen, Barbara Eichhorst, et al.. (2018). First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study. Blood. 132(Supplement 1). 185–185. 3 indexed citations
14.
15.
16.
17.
Zelenetz, Andrew D., Gilles Salles, Kylie D. Mason, et al.. (2016). Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma.. Journal of Clinical Oncology. 34(15_suppl). 7566–7566. 5 indexed citations
18.
19.
20.
Zelenetz, Andrew D., Mehrdad Mobasher, Luciano J. Costa, et al.. (2013). Safety and Efficacy Of Obinutuzumab (GA101) Plus CHOP Chemotherapy In First-Line Advanced Diffuse Large B-Cell Lymphoma: Results From The Phase 2 Gather Study (GAO4915g). Blood. 122(21). 1820–1820. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Celeste Bello Breakdown of academic impact, for papers by Deborah M. Stephens Breakdown of academic impact, for papers by Bret Wacker Breakdown of academic impact, for papers by Virginia Kelly Breakdown of academic impact, for papers by Monali Desai Breakdown of academic impact, for papers by Monica Else Breakdown of academic impact, for papers by Timothy J. Murphy Breakdown of academic impact, for papers by Kathryn Humphrey Breakdown of academic impact, for papers by Nicole Lamanna Breakdown of academic impact, for papers by Ilaria Del Giudice
Rankless by CCL
2026